George Chang

George Chang

Auto-generated profile, based on publicly available information

George Chang

Translational Modeling and Simulation, Pfizer Worldwide Research and Development, Groton, CT

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
LDLi Di
Li Di
JUJohn P. Umland
John P. Umland
GCGeorge Chang
George Chang
YHYouping Huang
Youping Huang
ZLZhen Lin
Zhen Lin
TLTheodore E. Liston
Theodore E. Liston
Species independence of brain tissue binding was assessed with a large number of structurally diverse compounds using equilibrium dialysis with brain homogenates of seven species and strains (Wistar Han rat, Sprague-Dawley rat, CD-1 mouse, Hartley guinea pig, beagle dog, cynomolgus monkey, and human). The results showed that the fractions unbound of the seven species and strains were strongly correlated with correlation coefficients ranging from 0.93 to 0.99. The cross-species/strain correlations were not significantly different from the interassay correlation with the same species. The linear correlation between Wistar Han and other species had a slope close to 1 and an intercept near 0. Based on orthogonal statistical analysis, no correction is needed for extrapolation of fraction unbound from Wistar Han rat to the other species or strains. Hence, brain tissue binding of Wistar Han rat can be used to obtain binding of other species and strains in drug discovery.

28 September 2021 in Spinal Cord Series and Cases
Verified
Journal Article
Open access
PDF file
RSRyan Shields
Ryan Shields
OSOlivia Sagan
Olivia Sagan
LRLogan Roebke
Logan Roebke
JMJosh Vander Maten
Josh Vander Maten
SSShailen Shah
Shailen Shah
SNSumayya Naz
Sumayya Naz
Introduction Sarcoidosis is a multisystem disease characterized histologically by noncaseating granulomas. Localization of sarcoidosis to the CNS is termed neurosarcoidosis, a complex and rare neuroinflammatory form of sarcoidosis. When the spinal cord is involved, lesions are often intradural. Here, we present a rare case of progressive myelopathy secondary to multifocal spinal extradural neurosarcoidosis with spinal cord compression and without pulmonary involvement. Case presentation A 29-year-old African American female presented to the emergency department with numbness and paresthesia of 2-month duration in her left lower extremity and 2-week duration in her right lower extremity. The patient reported difficulty ambulating, paresthesia below the umbilicus, and back pain radiating to bilateral lower extremities. She endorsed 9-month history of cough, subjective fevers, night sweats, and unintentional 15 kg weight loss. Examination revealed 4/5 strength in the left lower extremity. MRI of the brain and spinal cord revealed enhancing extradural lesions, with spinal cord compression at T8 measuring 1.3 × 1.9 cm. Lumbar puncture demonstrated oligoclonal bands and increased CSF neutrophils, lymphocytes, monocytes, and protein. T8 laminectomy with resection of the epidural lesion was performed. Histology showed granulomas, consistent with neurosarcoidosis. At follow-up, repeat spinal MRI revealed disease progression with intramedullary involvement. Long-term immunosuppressive treatment was eventually initiated with satisfactory response. Discussion This is a rare case of myelopathy secondary to spinal extradural neurosarcoidosis. Spinal neurosarcoidosis is predominantly an intradural process. Our review of the literature identified only seven cases of extradural neurosarcoidosis presenting with compressive myelopathy. Additional insight into management and rehabilitation following pathological diagnosis is of clinical significance.

1 May 1997 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
GCGeorge Chang
George Chang
RRRoger B Ruggeri
Roger B Ruggeri
Plasma lipids represent a major determinant for the development of coronary heart disease (CHD) and thus mortality in the industrialised world. Drug therapies that alter lipid levels have continued to demonstrate a mortality benefit in certain types of dyslipidaemia. Many enterprises are pursuing further agents that reduce the risk of CHD-events by established as well as novel mechanisms. This review provides a summary of the patents filed for such endeavours over the preceding two years.

30 November 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SJSamantha Jordan
Samantha Jordan
SRSangwoo Ryu
Sangwoo Ryu
WBWoodrow Burchett
Woodrow Burchett
CDCarl Davis
Carl Davis
RJRhys Jones
Rhys Jones
LDLi Di
Li Di